IpiNovyx Overview
- Year Founded
-
2021
- Status
-
Private
- Employees
-
5
- Latest Deal Type
-
Series A1
- Latest Deal Amount
-
$10M
- Investors
-
9
IpiNovyx General Information
Description
Developer of an immunoproteasome-modulating therapeutics platform designed to transform the treatment of autoimmune and inflammatory diseases. The company's tool helps inhibitors selectively target the immunoproteasome and modulate specific immune cell types, enabling patients to recover from autoimmune and inflammatory diseases and improve their health.
Contact Information
Website
www.ipinovyx.comCorporate Office
- 201 East Fifth Street
- Suite 2505
- Cincinnati, OH 45202
- United States
Corporate Office
- 201 East Fifth Street
- Suite 2505
- Cincinnati, OH 45202
- United States
IpiNovyx Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 3. Early Stage VC (Series A1) | 28-Sep-2023 | $10M | Completed | Pre-Clinical Trials | ||
| 2. Seed Round | 05-Oct-2021 | Completed | Pre-Clinical Trials | |||
| 1. University Spin-Out | 01-Jan-2021 | Completed | Startup |
IpiNovyx Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Series A-1 | ||||||||
| Seed-1 | ||||||||
| Seed | 57,988 | $0.000100 | $149.84 | $149.84 | 1x | $149.84 | 21.72% |
VC Exit Predictor
See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.
IpiNovyx Patents
IpiNovyx Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2026165077-A1 | Capped dipeptides as proteasome inhibitors | Pending | 28-Jan-2025 |
IpiNovyx Signals
IpiNovyx Investors (9)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Research Bridge Partners | Not-For-Profit Venture Capital | Minority | ||
| Alexandria Venture Investments | Venture Capital | Minority | ||
| Lilly USA | Corporation | Minority | ||
| Opaleye | Hedge Fund | Minority | ||
| Orange Grove Bio | Venture Capital | Minority |
IpiNovyx FAQs
-
When was IpiNovyx founded?
IpiNovyx was founded in 2021.
-
Where is IpiNovyx headquartered?
IpiNovyx is headquartered in Cincinnati, OH.
-
What is the size of IpiNovyx?
IpiNovyx has 5 total employees.
-
What industry is IpiNovyx in?
IpiNovyx’s primary industry is Drug Discovery.
-
Is IpiNovyx a private or public company?
IpiNovyx is a Private company.
-
What is the current valuation of IpiNovyx?
The current valuation of IpiNovyx is .
-
What is IpiNovyx’s current revenue?
The current revenue for IpiNovyx is .
-
How much funding has IpiNovyx raised over time?
IpiNovyx has raised $20M.
-
Who are IpiNovyx’s investors?
Research Bridge Partners, Alexandria Venture Investments, Lilly USA, Opaleye, and Orange Grove Bio are 5 of 9 investors who have invested in IpiNovyx.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process